Introduction
Fatigue is a common symptom in patients with IBD and has a substantial impact on quality of life.1-4 Its underlying pathophysiology in IBD is incompletely understood. 2 Even in IBD in remission, fatigue remains a disabling complaint. The aim of this multicentric study is to evaluate the prevalence of fatigue in patients with IBD in clinical remission and to identify associated factors.
Aims & Methods
We conducted a retrospective study across two Belgian IBD centers. Data were prospectively and serially obtained from all patients with IBD prior to each clinical visit through pre-visit questionnaires (PRO-2 and IBD disk). Clinical data were collected via the institutional IBD registry (UR-CARE). Patients were in PRO-2 clinical remission (UC: rectal bleeding score 0 and stool frequency score ≤1; CD: abdominal pain ≤1 and stool frequency ≤3). Fatigue was defined as a mean IBD-disk subscore ≥6, while severe fatigue was defined as a mean subscore of ≥8. Factors potentially correlating with fatigue, including clinical, biochemical, treatment- and disease-related factors, were assessed. Disability was assessed through all 9 remaining domains of the IBD-Disk. Multivariable logistic regression models were constructed to assess associations between clinical characteristics and the presence of (severe) fatigue. The relative contribution of disability to fatigue was assessed via separate multivariable logistic regression models.
Results
Of the 1320 patients, 1049 (79.4%) were in clinical remission. Among patients in remission, 41.4% reported fatigue and 19.9% experienced severe fatigue. A higher crude prevalence of fatigue was observed in Crohn’s disease compared with ulcerative colitis (49.6% vs 36.4%), but no independent association between disease type and fatigue was identified in multivariable logistic regression. In the regression model, female sex was strongly associated with both fatigue (OR=2.19, p<0.001) and severe fatigue (OR=2.20, p=0.001). Active smoking was independently associated with an increased likelihood of fatigue (OR=2.18, p=0.007) and severe fatigue (OR=2.60, p=0.005). A higher BMI was also associated with fatigue (OR=1.07, p<0.001) and severe fatigue (OR=1.09, p<0.001). No significant associations were observed for age, disease duration, disease extent or previous smoking status. Notably, exposure to advanced therapies was not associated with fatigue. Significant associations were observed between fatigue and multiple IBD-Disk domains. The strongest correlations were found for emotional functioning, education and work, and sleep disturbances (all p<0.001). Somatic domains such as abdominal pain, joint pain and regulation of defecation showed weaker yet still significant correlations (Table 1).
| Clinical model | Advanced therapy exposed | Age observation | BMI | UC | Disease duration | Female | Active smoker | Previous smoker |
|
| OR [95% CI] fatigue | 1,10 [0,70-1,72] | 0,99 [0,98-1,00] | 1,07** [1,03-1,11] | 1,05 [0,72-1,53] | 1,00 [0,98-1,02] | 2,19** [1,51-3,17] | 2,18** [1,24-3,87] | 1,15 [0,75-1,76] |
|
| OR [95%CI] severe fatigue | 1,29 [0,74-2,32] | 0,99 [0,98-1,00] | 1,09** [1,04-1,15] | 0,98 [0,61-1,57] | 0,99 [0,97-1,02] | 2,20** [1,39-3,52] | 2,60** [1,33-5,06] | 1,05 [0,61-1,80] |
|
| Disability model | Abdominal pain | Body image | Education and work | Emotions | Interpersonal interactions | Joint pain | Regulating defecation | Sexual function | Sleep |
| OR [95% CI] fatigue | 1.21** [1,10-1,33] | 1.10* [1,01-1,20] | 1.47** [1,29-1,68] | 1.32** [1,20-1,45] | 0.92 [0,79-1,05] | 1.07* [1,00-1,15] | 1.09 [0,98-1,20] | 0.98 [0,88-1,08] | 1.29** [1,20-1,39] |
| OR [95% CI] severe fatigue | 1.16* [1,02-1,32] | 1.11 [0,99-1,24] | 1.49** [1,28-1,74] | 1.35** [1,21-1,53] | 0.91 [0,77-1,08] | 1.09 [0,99-1,20] | 1.06 [0,92-1,21] | 0.97 [0,85-1,09] | 1.31* [1,19-1,45] |
Table 1: Multivariate clinical model assessing risk factors for (severe) fatigue. Multivariate disablity model assessing symptom clusters correlated with (severe) fatigue. (* = p<0.05;**=p<0.01) (OR=odds ratio; CI=confidence interval; BMI=body mass index; UC=ulcerative colitis)
Conclusion
Fatigue is highly prevalent among patients with IBD in clinical remission. Patient related factors contribute stronger to fatigue than disease related factors. Our findings support that fatigue in IBD is a multidimensional phenomenon and strongly associated with psychosocial IBD-Disk domains.
References
- Borren NZ, van der Woude CJ, Ananthakrishnan AN. Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2019;16:247–259.
- Van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(2):131–143.
- D'Silva A, Fox DE, Nasser Y, et al. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis. Clin Gastroenterol Hepatol. 2022;20(5):995–1009.e7.
- Casanova MJ, Chaparro M, Barreiro-de Acosta M, et al. Prevalence and determinants of fatigue in patients with inflammatory bowel disease: a cross-sectional survey from the GETAID. J Crohns Colitis. 2021;15(1):104–112
Disclosure
Dr. Filip Baert: Grants: Abbvie, Amgen, Eurogenerics, J&J, Takeda - Lecture fees/Speakers Bureau: AbbVie, Arena Pharmaceuticals, Celltrion, Ferring, Galapagos, J&J, Lilly, Merck Sharp & Dohme, Pfizer, and Takeda - Consultancy: AbbVie, Abivax, Amgen, Arena Pharmaceuticals, Celgene, Celltrion, Ferring, Fresenius Kabi, J&J, Merck Sharp & Dohme, Pfizer, Sandoz
Dr. Lieven Pouillon: Advisory board fees from AbbVie, Alphasigma, Celltrion, Galápagos, Janssen-Cilag, Sandoz and Takeda - Consultancy fees from Ipsos NV and Ismar Healthcare funded by Viatris - Presentation fees from AbbVie, Alphasigma, Celltrion, Eli Lilly, Ferring , Galápagos and Pfizer; and personal fees (congress support) from AbbVie, EG, Ferring, Galápagos, Janssen-Cilag, Norgine and Takeda.
Dr. Peter Bossuyt: Grant support for research from AbbVie, EG - Consulting fee from AbbVie, Bristol Meyers Squibb, CIRC, Galapagos, Janssen, Jeito capital, Lilly, Pentax, Pfizer, PSI-CRO, Roche, Takeda, Tetrameros - Speakers fee from AbbVie, AMC ICP, Amgen, Bristol Myers Squibb, Celltrion, Dr Falk Benelux, EG, Galapagos, Globalport, Lilly, Medtalks, Materia Prima, Pentax, Springer Media.